Catalog No.: PC-22141Not For Human Use, Lab Use Only.
DBPR728 is an oral bioavailable acyl-based prodrug of 6K465, which is a potent selective Aurora A (AURKA) inhibitor, effectively inhibits cancer cells overexpressing c-MYC- and/or N-MYC.
DBPR728 is an oral bioavailable acyl-based prodrug of 6K465, which is a potent selective Aurora A (AURKA) inhibitor, effectively inhibits cancer cells overexpressing c-MYC- and/or N-MYC.
DBPR728 induced durable tumor regression of c-MYC- and/or N-MYC- overexpressing xenografts including SCLC, triple-negative breast cancer (TNBC), hepatocellular carcinoma and medulloblastoma.
DBPR728 at 300 mg/kg induced c-MYC reduction and cell apoptosis in the tumor xenografts for more than 7 days.
DBPR728 also synergized with the mTOR inhibitor everolimus to suppress c-MYC- or N-MYC- driven SCLC.
